Allostery Investments LP bought a new stake in Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 950,166 shares of the company's stock, valued at approximately $998,000. Context Therapeutics accounts for about 1.0% of Allostery Investments LP's portfolio, making the stock its 17th largest holding. Allostery Investments LP owned about 1.27% of Context Therapeutics as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. State Street Corp raised its position in Context Therapeutics by 21.5% in the third quarter. State Street Corp now owns 111,907 shares of the company's stock valued at $219,000 after purchasing an additional 19,800 shares during the period. Geode Capital Management LLC raised its holdings in shares of Context Therapeutics by 9.2% during the 4th quarter. Geode Capital Management LLC now owns 628,729 shares of the company's stock valued at $661,000 after buying an additional 52,830 shares during the period. Franklin Resources Inc. acquired a new position in Context Therapeutics during the 3rd quarter worth approximately $3,689,000. Blue Owl Capital Holdings LP boosted its holdings in Context Therapeutics by 17.5% in the 4th quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company's stock worth $6,676,000 after acquiring an additional 946,638 shares during the period. Finally, Walleye Capital LLC grew its position in Context Therapeutics by 51.7% in the fourth quarter. Walleye Capital LLC now owns 166,306 shares of the company's stock valued at $175,000 after acquiring an additional 56,651 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company's stock.
Context Therapeutics Trading Up 0.8 %
NASDAQ CNTX traded up $0.01 on Friday, hitting $0.87. 30,000 shares of the stock traded hands, compared to its average volume of 300,208. The stock has a 50-day moving average of $0.78 and a 200 day moving average of $1.16. Context Therapeutics Inc. has a twelve month low of $0.55 and a twelve month high of $2.75. The company has a market capitalization of $78.01 million, a P/E ratio of -0.96 and a beta of 2.18.
Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. As a group, equities research analysts expect that Context Therapeutics Inc. will post -0.51 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on the stock. JMP Securities began coverage on shares of Context Therapeutics in a research note on Wednesday, January 8th. They issued an "outperform" rating and a $4.00 target price for the company. HC Wainwright reissued a "buy" rating and issued a $5.00 price objective on shares of Context Therapeutics in a research report on Friday, March 21st. D. Boral Capital reaffirmed a "buy" rating and set a $9.00 target price on shares of Context Therapeutics in a research report on Tuesday, April 29th. William Blair reissued an "outperform" rating on shares of Context Therapeutics in a report on Tuesday, April 29th. Finally, Citizens Jmp upgraded Context Therapeutics to a "strong-buy" rating in a report on Wednesday, January 8th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $6.17.
Read Our Latest Report on Context Therapeutics
Context Therapeutics Profile
(
Free Report)
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Further Reading
Before you consider Context Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.
While Context Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
